Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer
Frontiers in Cellular and Infection Microbiology · 16.11.2023 · 13
DOI: 10.3389/fcimb.2023.1298264 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 16.11.2023. Verfasst von Lena Van Dingenen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medical Applications, Belgian Nuclear Research Centre, SCK CEN, Mol, Belgium. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Colorectal Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 255 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and poses a major burden on the human health worldwide. At the moment, treatment of CRC consists of surgery in combination with (neo)adjuvant chemotherapy and/or radiotherapy. More recently, immune checkpoint blockers (ICBs) have also been approved for CRC treatment. In addition, recent studies have shown that radiotherapy and ICBs act synergistically, with radiotherapy stimulating the immune system that is activated by ICBs. However, both treatments are also associated with severe toxicity and efficacy issues, which can lead to temporary or permanent discontinuation of these treatment programs. There's growing evidence pointing to the gut microbiome playing a role in these issues. Some microorganisms seem to contribute to radiotherapy-associated toxicity and hinder ICB efficacy, while others seem to reduce radiotherapy-associated toxicity or enhance ICB efficacy. Consequently, fecal microbiota transplantation (FMT) has been applied to reduce radio- and immunotherapy-related toxicity and enhance their efficacies. Here, we have reviewed the currently available preclinical and clinical data in CRC treatment, with a focus on how the gut microbiome influences radio- and immunotherapy toxicity and efficacy and if these treatments could benefit from FMT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nuclear Medical Applications, Belgian Nuclear Research Centre, SCK CEN, Mol, Belgium.
- Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, Faculty of Medicine, University of Antwerp, Antwerp, Belgium.
- Molecular Pathology Group, Laboratory of Cell Biology and Histology, Faculty of Medicine, University of Antwerp, Antwerp, Belgium.
- Bioinformatics Group, Center for Informatics Science, School of Information Technology and Computer Science, Nile University, Giza, Egypt.
Zitieren
APA
Van Dingenen, L., Segers, C., Wouters, S., Mysara, M., Leys, N., Kumar-Singh, S., Malhotra-Kumar, S., & Van Houdt, R. (2023). Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer. Frontiers in Cellular and Infection Microbiology, 13. https://doi.org/10.3389/fcimb.2023.1298264
Vancouver
Van Dingenen L, Segers C, Wouters S, Mysara M, Leys N, Kumar-Singh S, et al. Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer. Frontiers in Cellular and Infection Microbiology. 2023;13. doi:10.3389/fcimb.2023.1298264
BibTeX
@article{VanDingenen2023,
author = {Van Dingenen, Lena and Segers, Charlotte and Wouters, Shari and Mysara, Mohamed and Leys, Natalie and Kumar-Singh, Samir and Malhotra-Kumar, Surbhi and Van Houdt, Rob},
title = {Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
volume = {13},
doi = {10.3389/fcimb.2023.1298264}
}
EUVIMED